Nanomedicines impacts in ocular delivery and targeting

Nanotechnology in Health Care

Volumn , Issue , 2012, Pages 43-106

  Omidi, Yadollah ^a   Barar, Jaleh ^a   Hamzeiy, Hossein ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881764255     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814267359     Document Type: Chapter

References (193)

1. Adibkia, K., Omidi, Y., Siahi, M.R., Javadzadeh, A.R., Barzegar-Jalali, M., Barar, J., Maleki, N., Mohammadi, G., and Nokhodchi, A. (2007a). Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J. Ocul. Pharmacol. Ther., 23, pp. 421-432.
2. Adibkia, K., Siahi Shadbad, M.R., Nokhodchi, A., Javadzedeh, A., Barzegar-Jalali, M., Barar, J., Mohammadi, G., and Omidi, Y. (2007b). Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J. Drug Target, 15, pp. 407-416.
3. Agnihotri, S.M., and Vavia, P.R. (2009). Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine, 5, pp. 90-95.
4. Ahmed, I. (2003). The noncorneal route in ocular drug delivery. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 335-363. Marcel Dekker, New York.
5. Ambati, J., Canakis, C.S., Miller, J.W., Gragoudas, E.S., Edwards, A., Weissgold, D.J., Kim, I., Delori, F.C., and Adamis, A.P. (2000). Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci., 41, pp. 1181-1185.
6. Ashton, P. (2006). Retinal drug delivery. In Intraocular Drug Delivery (ed. G.J. Jaffe, P. Ashton, and P.A. Pearson), pp. 1-25. Taylor & Francis Group, LLC, New York.
7. Asrani, S., Goldberg, M.F., and Zeimer, R. (2006). Thermal-sensitive liposomes. In Intraocular Drug Delivery (ed. G.J. Jaffe, P. Ashton, and P.A. Pearson), pp. 143-156. Taylor & Francis Group, LLC, New York.
8. Athanasiou, K.A., Niederauer, G.G., and Agrawal, C.M. (1996). Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials, 17, pp. 93-102.
9. Atluri, H., Anand, B.S., Patel, J., and Mitra, A.K. (2004). Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp. Eye Res., 78, pp. 815-822.
10. Attama, A.A., Reichl, S., and Muller-Goymann, C.C. (2008). Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm., 355, pp. 307-313.
11. Attar, M., Shen, J., Ling, K.H., and Tang-Liu, D. (2005). Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters. Expert Opin. Drug Deliv., 2, pp. 891-908.
12. Auricchio, A. (2003). Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye. Vision Res., 43, pp. 913-918.
13. Auricchio, A., Rivera, V.M., Clackson, T., O'Connor, E.E., Maguire, A.M., Tolentino, M.J., Bennett, J., and Wilson, J.M. (2002). Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol. Ther., 6, pp. 238-242.
14. Badawi, A.A., El-Laithy, H.M., El Qidra, R.K., El, M.H., and El, d.M. (2008). Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res., 31, pp. 1040-1049.
15. Bainbridge, J.W., and Ali, R.R. (2008). Ocular gene therapy trials due to report this year; keeping an eye on clinical trials in 2008. Gene Ther. (in press).
16. Bainbridge, J.W., Tan, M.H., and Ali, R.R. (2006). Gene therapy progress and prospects: the eye. Gene Ther., 13, pp. 1191-1197.
17. Bakri, S.J., and Kaiser, P.K. (2006). Antiangiogenic agents: intravitreal injection. In Intraocular Drug Delivery (ed. G.J. Jaffe, P. Ashton, and P.A. Pearson), pp. 71-84. Taylor & Francis Group, LLC, New York.
18. Barar, J., Javadzadeh, A.R., and Omidi, Y. (2008). Ocular novel drug delivery: impacts of membranes and barriers. Expert. Opin. Drug Deliv., 5, pp. 567-581.
19. Barza, M., Stuart, M., and Szoka, F., Jr. (1987). Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest. Ophthalmol. Vis. Sci., 28, pp. 893-900.
20. Baudouin, C. (1996). Side effects of antiglaucomatous drugs on the ocular surface. Curr. Opin. Ophthalmol., 7, pp. 80-86.
21. Bejjani, R.A., BenEzra, D., Cohen, H., Rieger, J., Andrieu, C., Jeanny, J.C., Gollomb, G., and Behar-Cohen, F. (2005). Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis., 11, pp. 124-132.
22. Bill, A. (1986). The blood-aqueous barrier. Trans. Ophthalmol. Soc. U.K., 105 (Pt 2), pp. 149-155.
23. Bloquel, C., Bourges, J.L., Touchard, E., Berdugo, M., BenEzra, D., and Behar-Cohen, F. (2006). Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv. Drug Deliv. Rev., 58, pp. 1224-1242.
24. Boado, R.J., Zhang, Y., Zhang, Y., Xia, C.F., Wang, Y., and Pardridge, W.M. (2008). Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng., 99, pp. 475-484.
25. Bridges, C.C., El-Sherbeny, A., Roon, P., Ola, M.S., Kekuda, R., Ganapathy, V., Camero, R.S., Cameron, P.L., and Smith, S.B. (2001). A comparison of caveolae and caveolin-1 to folate receptor alpha in retina and retinal pigment epithelium. Histochem. J., 33, pp. 149-158.
26. Bu, H.Z., Gukasyan, H.J., Goulet, L., Lou, X.J., Xiang, C., and Koudriakova, T. (2007). Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr. Drug Metab., 8, pp. 91-107.
27. Bucolo, C., Maltese, A., Maugeri, F., Busa, B., Puglisi, G., and Pignatello, R. (2004). Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J. Pharm. Pharmacol., 56, pp. 841-846.
28. Cai, X., Conley, S., and Naash, M. (2008). Nanoparticle applications in ocular gene therapy. Vision Res., 48, pp. 319-324.
29. Calvo, P., Alonso, M.J., Vila-Jato, J.L., and Robinson, J.R. (1996). Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol., 48, pp. 1147-1152.
30. Camelo, S., Lajavardi, L., Bochot, A., Goldenberg, B., Naud, M.C., Brunel, N., Lescure, B., Klein, C., Fattal, E., Behar-Cohen, F., and De, K.Y. (2009). Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J. Ocul. Pharmacol. Ther., 25, pp. 9-21.
31. Cantrill, H.L., Henry, K., Melroe, N.H., Knobloch, W.H., Ramsay, R.C., and Balfour, H.H., Jr. (1989). Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology, 96, pp. 367-374.
32. Cao, Y., Zhang, C., Shen, W., Cheng, Z., Yu, L.L., and Ping, Q. (2007). Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J. Control Release, 120, pp. 186-194.
33. Chang, J.E., Basu, S.K., and Lee, V.H. (2000). Air-interface condition promotes the formation of tight corneal epithelial cell layers for drug transport studies. Pharm. Res., 17, pp. 670-676.
34. Chastain, J.E. (2003). General considerations in ocular drug delivery. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 59-108. Marcel Dekker, New York.
35. Chiou, G.C., Shen, Z.F., and Zheng, Y.Q. (1991). Systemic absorption of oxytocin and vasopressin through eyes in rabbits. J. Ocul. Pharmacol., 7, pp. 351-359.
36. Choy, Y.B., Park, J.H., McCarey, B.E., Edelhauser, H.F., and Prausnitz, M.R. (2008). Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time. Invest. Ophthalmol. Vis. Sci., 49, pp. 4808-4815.
37. Costabile, B.S. (1998). Treatment of cytomegalovirus retinitis with intraocular implants. AORN J., 67, pp. 356-368.
38. Dartt, D.A., Hodges, R.R., and Zoukhri, D. (2006). Tear and their secretion. In The Biology of Eye (ed. J. Fischbarg), pp. 21-82. Academic Press, New York.
39. Davis, A.A., Bernstein, P.S., Bok, D., Turner, J., Nachtigal, M., and Hunt, R.C. (1995). A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture. Invest. Ophthalmol. Vis. Sci., 36, pp. 955-964.
40. Davis, J.L., Gilger, B.C., and Robinson, M.R. (2004). Novel approaches to ocular drug delivery. Curr. Opin. Mol. Ther., 6, pp. 195-205.
41. De Campos, A.M., Diebold, Y., Carvalho, E.L., Sanchez, A., and Alonso, M.J. (2004). Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res., 21, pp. 803-810.
42. De Campos, A.M., Sanchez, A., and Alonso, M.J. (2001). Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm., 224, pp. 159-168.
43. Dey, S., and Mitra, A.K. (2005). Transporters and receptors in ocular drug delivery: opportunities and challenges. Expert Opin. Drug Deliv., 2, pp. 201-204.
44. Dey, S., Patel, J., Anand, B.S., Jain-Vakkalagadda, B., Kaliki, P., Pal, D., Ganapathy, V., and Mitra, A.K. (2003). Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci., 44, pp. 2909-2918.
45. Diebold, Y., Jarrin, M., Saez, V., Carvalho, E.L., Orea, M., Calonge, M., Seijo, B., and Alonso, M.J. (2007). Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials, 28, pp. 1553-1564.
46. Dillen, K., Vandervoort, J., Van den Mooter, G., and Ludwig, A. (2006). Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int. J. Pharm., 314, pp. 72-82.
47. Dong, X., Shi, W., Yuan, G., Xie, L., Wang, S., and Lin, P. (2006). Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis. Graefes Arch. Clin. Exp. Ophthalmol., 244, pp. 492-497.
48. Duan, X., and Sheardown, H. (2006). Dendrimer crosslinked collagen as a corneal tissue engineering scaffold: mechanical properties and corneal epithelial cell interactions. Biomaterials, 27, pp. 4608-4617.
49. Dunn, K.C., Aotaki-Keen, A.E., Putkey, F.R., and Hjelmeland, L.M. (1996). ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res., 62, pp. 155-169.
50. Duvvuri, S., Majumdar, S., and Mitra, A.K. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther., 3, pp. 45-56.
51. Duvvuri, S., Majumdar, S., and Mitra, A.K. (2004). Role of metabolism in ocular drug delivery. Curr. Drug Metab, 5, pp. 507-515.
52. Einmahl, S., Capancioni, S., Schwach-Abdellaoui, K., Moeller, M., Behar-Cohen, F., and Gurny, R. (2001). Therapeutic applications of viscous and injectable poly(ortho esters). Adv. Drug Deliv. Rev., 53, pp. 45-73.
53. El-Beik, S., and Elligott, R. (2007). Macular degeneration - Advances in treatment. Hospital Pharmacist, 14, pp. 155-160.
54. Fenwick, B.W., and Cullis, P.R. (2008). Liposomal nanomedicines. Expert. Opin. Drug Deliv., 5, pp. 25-44.
55. Fischbarg, J. (2006a) The Biology of the Eye, 10th edn. Elsevier Science, Amsterdam.
56. Fischbarg, J. (2006b). The corneal endothelim. In The Biology of Eye (ed. J. Fischbarg), pp. 113-125. Academic Press, New York.
57. Fischbarg, J., Diecke, F.P., Iserovich, P., and Rubashkin, A. (2006). The role of the tight junction in paracellular fluid transport across corneal endothelium. electro-osmosis as a driving force. J. Membr. Biol., 210, pp. 117-130.
58. Frank, R.G. (2003). New estimates of drug development costs. J. Health Econ., 22, pp. 325-330.
59. Freddo, T.F. (2001). Shifting the paradigm of the blood-aqueous barrier. Exp. Eye Res., 73, pp. 581-592.
60. Fullard, R.J., and Tucker, D. (1994). Tear protein composition and the effects of stimulus. Adv. Exp. Med. Biol., 350, pp. 309-314.
61. Ganapathy, M.E., and Ganapathy, V. (2005). Amino Acid Transporter ATB0+ as a delivery system for drugs and prodrugs. Curr. Drug Targets: Immune. Endocr. Metabol. Disord., 5, pp. 357-364.
62. Gao, J., Sun, X., Yatsula, V., Wymore, R.S., and Mathias, R.T. (2000). Isoform-specific function and distribution of Na/K pumps in the frog lens epithelium. J. Membr. Biol., 178, pp. 89-101.
63. Gardner, T.W., Antonetti, D.A., Barber, A.J., Lieth, E., and Tarbell, J.A. (1999). The molecular structure and function of the inner blood-retinal barrier. Penn State Retina Research Group. Doc. Ophthalmol., 97, pp. 229-237.
64. Gaudana, R., Jwala, J., Boddu, S.H., and Mitra, A.K. (2009). Recent perspectives in ocular drug delivery. Pharm. Res., 26, pp. 1197-1216.
65. Gerhart, D.Z., Leino, R.L., and Drewes, L.R. (1999). Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience, 92, pp. 367-375.
66. Ghate, D., and Edelhauser, H.F. (2006). Ocular drug delivery. Expert. Opin. Drug Deliv., 3, pp. 275-287.
67. Giannavola, C., Bucolo, C., Maltese, A., Paolino, D., Vandelli, M.A., Puglisi, G., Lee, V.H., and Fresta, M. (2003). Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm. Res., 20, pp. 584-590.
68. Gillies, M.C., Su, T., and Naidoo, D. (1995). Electrical resistance and macromolecular permeability of retinal capillary endothelial cells in vitro. Curr. Eye Res., 14, pp. 435-442.
69. Hamalainen, K.M., Kananen, K., Auriola, S., Kontturi, K., and Urtti, A. (1997). Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. Ophthalmol. Vis. Sci., 38, pp. 627-634.
70. Hamann, S. (2002). Molecular mechanisms of water transport in the eye. Int. Rev. Cytol., 215, pp. 395-431.
71. Zeuthen, T., and Wilfred, D. (eds) Molecular Mechanisms of Water Transport Across Biological Membranes, vol. 215, pp. 395-431. Academic Press.
72. Hamilton, M.M., Brough, D.E., McVey, D., Bruder, J.T., King, C.R., and Wei, L.L. (2006). Repeated administration of adenovector in the eye results in efficient gene delivery. Invest. Ophthalmol. Vis. Sci., 47, pp. 299-305.
73. Hayek, S., Scherrer, M., Barthelmes, D., Fleischhauer, J.C., Kurz-Levin, M.M., Menghini, M., Helbig, H., and Sutter, F.K. (2007). First clinical experience with anecortave acetate (Retaane). Klin. Monatsbl. Augenheilkd., 224, pp. 279-281.
74. Herrero-Vanrell, R., and Refojo, M.F. (2001). Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev., 52, pp. 5-16.
75. Hillaireau, H., Le, D.T., and Couvreur, P. (2006). Polymer-based nanoparticles for the delivery of nucleoside analogues. J. Nanosci. Nanotechnol., 6, pp. 2608-2617.
76. Holash, J.A., and Stewart, P.A. (1993). The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res., 629, pp. 218-224.
77. Hornof, M., Toropainen, E., and Urtti, A. (2005). Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm., 60, pp. 207-225.
78. Hosoya, K., Horibe, Y., Kim, K.J., and Lee, V.H. (1998). Nucleoside transport mechanisms in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci., 39, pp. 372-377.
79. Hosoya, K., Lee, V.H., and Kim, K.J. (2005). Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm., 60, pp. 227-240.
80. Hosoya, K., Tomi, M., Ohtsuki, S., Takanaga, H., Ueda, M., Yanai, N., Obinata, M., and Terasaki, T. (2001). Conditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat. Exp. Eye Res., 72, pp. 163-172.
81. Huang, H.S., Schoenwald, R.D., and Lach, J.L. (1983a). Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. J. Pharm. Sci., 72, pp. 1272-1279.
82. Huang, H.S., Schoenwald, R.D., and Lach, J.L. (1983b). Corneal penetration behavior of beta-blocking agents III: In vitro-in vivo correlations. J. Pharm. Sci., 72, pp. 1279-1281.
83. Hunt, R.C., Dewey, A., and Davis, A.A. (1989). Transferrin receptors on the surfaces of retinal pigment epithelial cells are associated with the cytoskeleton. J. Cell Sci., 92 (Pt 4), pp. 655-666.
84. Jabs, D.A. (1995). Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Infect. Agents Dis., 4, pp. 131-142.
85. Janoria, K.G., Gunda, S., Boddu, S.H., and Mitra, A.K. (2007). Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv., 4, pp. 371-388.
86. Jentsch, T.J., Keller, S.K., and Wiederholt, M. (1985). Ion transport mechanisms in cultured bovine corneal endothelial cells. Curr. Eye Res., 4, pp. 361-369.
87. Jose Alonso, M. (2004). Nanomedicines for overcoming biological barriers. Biomed. Pharmacother., 58, pp. 168-172.
88. Ju, M., Mailhos, C., Bradley, J., Dowie, T., Ganley, M., Cook, G., Calias, P., Lange, N., Adamis, A.P., Shima, D.T., and Robinson, G.S. (2008). Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest. Ophthalmol. Vis. Sci., 49, pp. 662-670.
89. Karla, P.K., Pal, D., Quinn, T., and Mitra, A.K. (2007). Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J. Pharm., 336, pp. 12-21.
90. Kassem, M.A., Abdel Rahman, A.A., Ghorab, M.M., Ahmed, M.B., and Khalil, R.M. (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm., 340, pp. 126-133.
91. Kaur, I.P., Garg, A., Singla, A.K., and Aggarwal, D. (2004). Vesicular systems in ocular drug delivery: an overview. Int. J. Pharm., 269, pp. 1-14.
92. Kayser, O., Lemke, A., and Hernandez-Trejo, N. (2005). The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 6, pp. 3-5.
93. Kim, S.H., Lutz, R.J., Wang, N.S., and Robinson, M.R. (2007). Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res., 39, pp. 244-254.
94. Kimura, H., and Ogura, Y. (2001). Biodegradable polymers for ocular drug delivery. Ophthalmologica, 215, pp. 143-155.
95. Klyce, S.D., and Crosson, C.E. (1985). Transport processes across the rabbit corneal epithelium: a review. Curr. Eye Res., 4, pp. 323-331.
96. Kobayashi, H., Shiraki, K., and Ikada, Y. (1992). Toxicity test of biodegradable polymers by implantation in rabbit cornea. J. Biomed. Mater. Res., 26, pp. 1463-1476.
97. Koizumi, K., Poulaki, V., Doehmen, S., Welsandt, G., Radetzky, S., Lappas, A., Kociok, N., Kirchhof, B., and Joussen, A.M. (2003). Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest. Ophthalmol. Vis. Sci., 44, pp. 2184-2191.
98. Kompella, U.B., Sundaram, S., Raghava, S., and Escobar, E.R. (2006). Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol. Vis., 12, pp. 1185-1198.
99. Kothuri, M.K., Pinnamaneni, S., Das, N.G., and Das, S.K. (2003). Microparticles and nanoparticles in ocular drug delivery. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 437-466. Marcel Dekker, New York.
100. Kuang, K., Li, Y., Yiming, M., Sanchez, J.M., Iserovich, P., Cragoe, E.J., Diecke, F.P., and Fischbarg, J. (2004). Intracellular [Na+], Na+ pathways, and fluid transport in cultured bovine corneal endothelial cells. Exp. Eye Res., 79, pp. 93-103.
101. Kurz, D., and Ciulla, T.A. (2002). Novel approaches for retinal drug delivery. Ophthalmol. Clin. North Am., 15, pp. 405-410.
102. Kyyronen, K., and Urtti, A. (1990). Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine. Invest. Ophthalmol. Vis. Sci., 31, pp. 1827-1833.
103. la Cour, M., and Ehinger, B. (2006). The retina. In The Biology of Eye (ed. J. Fischbarg), pp. 195-252. Academic Press, New York.
104. Lang, J.C. (1995). Ocular drug delivery conventional ocular formulation. Adv. Drug Deliv. Rev., 16, pp. 39-43.
105. Lazic, R., and Gabric, N. (2007). Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 114, pp. 1179-1185.
106. Le, M.G., Stieger, K., Smith, A.J., Weber, M., Deschamps, J.Y., Nivard, D., Mendes-Madeira, A., Provost, N., Pereon, Y., Cherel, Y., Ali, R.R., Hamel, C., Moullier, P., and Rolling, F. (2007). Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther., 14, pp. 292-303.
107. Lee, B., Litt, M., and Buchsbaum, G. (1992). Rheology of the vitreous body: part 1: Viscoelasticity of human vitreous. Biorheology, 29, pp. 521-533.
108. Lee, B., Litt, M., and Buchsbaum, G. (1994a). Rheology of the vitreous body: part 2. Viscoelasticity of bovine and porcine vitreous. Biorheology, 31, pp. 327-338.
109. Lee, B., Litt, M., and Buchsbaum, G. (1994b). Rheology of the vitreous body: part 3. Concentration of electrolytes, collagen and hyaluronic acid. Biorheology, 31, pp. 339-351.
110. Lee, T.W., and Robinson, J.R. (2004). Drug delivery to the posterior segment of the eye III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection. J. Ocul. Pharmacol. Ther., 20, pp. 55-64.
111. Lee, V.H. (1990). New directions in the optimization of ocular drug delivery. J. Ocul. Pharmacol., 6, pp. 157-164.
112. Lee, V.H., Carson, L.W., Kashi, S.D., and Stratford, R.E., Jr. (1986). Metabolic and permeation barriers to the ocular absorption of topically applied enkephalins in albino rabbits. J. Ocul. Pharmacol., 2, pp. 345-352.
113. Leeming, J.P. (1999). Treatment of ocular infections with topical antibacterials. Clin. Pharmacokinet., 37, pp. 351-360.
114. Lehr, C.M., Lee, Y.H., and Lee, V.H. (1994). Improved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci., 35, pp. 2809-2814.
115. Li, H., Tran, V.V., Hu, Y., Mark, S.W., Barns, C.J., and Tombran-Tink, J. (2006). A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye Res., 83, pp. 824-833.
116. Liaw, J., Chang, S.F., and Hsiao, F.C. (2001). In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles. Gene Ther., 8, pp. 999-1004.
117. Lin, H., Kenyon, E., and Miller, S.S. (1992). Na-dependent pHi regulatory mechanisms in native human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci., 33, pp. 3528-3538.
118. Liu, D., Ren, T., and Gao, X. (2003). Cationic transfection lipids. Curr. Med. Chem., 10, pp. 1307-1315.
119. Lo, W.K., Mills, A., Zhang, W., and Zhu, H. (1991). Polarized distribution of coated pits and coated vesicles in the rat lens: an electron microscopy and WGA-HRP tracer study. Curr. Eye Res., 10, pp. 1151-1163.
120. Lo, W.K., Zhou, C.J., and Reddan, J. (2004). Identification of caveolae and their signature proteins caveolin 1 and 2 in the lens. Exp. Eye Res., 79, pp. 487-498.
121. Lopez-Cortes, L.F., Pastor-Ramos, M.T., Ruiz-Valderas, R., Cordero, E., Uceda-Montanes, A., Claro-Cala, C.M., and Lucero-Munoz, M.J. (2001). Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci., 42, pp. 1024-1028.
122. Loutsch, J.M., Ong, D., and Hill, J.M. (2003). Dendrimers: an innovative and enhanced ocular drug delivery system. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 467-492. Marcel Dekker, New York.
123. Ludwig, A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Delivery Rev., 57, pp. 1595-1639.
124. Macha, S., and Mitra, A.K. (2003). Overview of ocular drug delivery. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 1-12. Marcel Dekker, New York.
125. Maguire, A.M., and Bennett, J. (2006). Gene therapy for retinal disease. In Intraocular Drug Delivery (ed. G.J. Jaffe, P. Ashton, and P.A. Pearson), pp. 157-173. Taylor & Francis Group, LLC, New York.
126. Mannermaa, E., Vellonen, K.S., and Urtti, A. (2006). Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev., 58, pp. 1136-1163.
127. Marano, R.J., Toth, I., Wimmer, N., Brankov, M., and Rakoczy, P.E. (2005). Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther., 12, pp. 1544-1550.
128. Marie, O., Thillaye-Goldenberg, B., Naud, M.C., and de Kozak, Y. (1999). Inhibition of endotoxin-induced uveitis and potentiation of local TNF-alpha and interleukin-6 mRNA expression by interleukin-13. Invest. Ophthalmol. Vis. Sci., 40, pp. 2275-2282.
129. McLaughlin, B.J., Caldwell, R.B., Sasaki, Y., and Wood, T.O. (1985). Freeze-fracture quantitative comparison of rabbit corneal epithelial and endothelial membranes. Curr. Eye Res., 4, pp. 951-961.
130. Mitra, A.K., Anand, B.S., and Duvvuri, S. (2006). Drug delivery to the eye. In The Biology of Eye (ed. J. Fischbarg), pp. 307-351. Academic Press, New York.
131. Mo, Y., Barnett, M.E., Takemoto, D., Davidson, H., and Kompella, U.B. (2007). Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol. Vis., 13, pp. 746-757.
132. Muccioli, C., and Belfort, R., Jr. (2000). Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Braz. J. Med. Biol. Res., 33, pp. 779-789.
133. Muyldermans, S., Baral, T.N., Retamozzo, V.C., De, B.P., De, G.E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V.K., Revets, H., Rothbauer, U., Stijlemans, B., Tillib, S., Wernery, U., Wyns, L., Hassanzadeh-ghassabeh, G., and Saerens, D. (2009). Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol., 128, pp. 178-183.
134. Myles, M.E., Neumann, D.M., and Hill, J.M. (2005). Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev., 57, pp. 2063-2079.
135. Andrieu-Soler, C., Bejjani, R.A., de Bizemont, T., Normand, N., BenEzra, D., and Behar-Cohen, F. (2006). Ocular gene therapy: a review of nonviral strategies. Mol. Vis., 12, pp. 1334-1347.
136. Nicolazzi, C., Garinot, M., Mignet, N., Scherman, D., and Bessodes, M. (2003). Cationic lipids for transfection. Curr. Med. Chem., 10, pp. 1263-1277.
137. Nishiyama, N., Iriyama, A., Jang, W.D., Miyata, K., Itaka, K., Inoue, Y., Takahashi, H., Yanagi, Y., Tamaki, Y., Koyama, H., and Kataoka, K. (2005). Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer. Nat. Mater., 4, pp. 934-941.
138. Omidi, Y., Barar, J., Ahmadian, S., Heidari, H.R., and Gumbleton, M. (2008). Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochem. Funct. (in press).
139. Omidi, Y., Barar, J., and Akhtar, S. (2005). Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr. Drug Deliv., 2, pp. 429-441.
140. Omidi, Y., Campbell, L., Barar, J., Connell, D., Akhtar, S., and Gumbleton, M. (2003a). Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res., 990, pp. 95-112.
141. Omidi, Y., and Gumbleton, M. (2005). Biological membranes and barriers. In Biomaterials for Delivery and Targeting of Proteins Nucleic Acids (ed. R.I. Mahato), pp. 232-274. CRC Press, New York.
142. Omidi, Y., Hollins, A.J., Benboubetra, M., Drayton, R., Benter, I.F., and Akhtar, S. (2003b). Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target, 11, pp. 311-323.
143. Palmgren, J.J., Toropainen, E., Auriola, S., and Urtti, A. (2002). Liquid chromatographic-electrospray ionization mass spectrometric analysis of neutral and charged polyethylene glycols. J. Chromatogr. A, 976, pp. 165-170.
144. Parascandola, J. (1991). The development of the Draize test for eye toxicity. Pharm. Hist, 33, pp. 111-117.
145. Pardridge, W.M. (2007). Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J. Control Release, 122, pp. 345-348.
146. Patravale, V.B., Date, A.A., and Kulkarni, R.M. (2004). Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol., 56, pp. 827-840.
147. Pece, A., Isola, V., Vadala, M., and Calori, G. (2007). Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina, 27, pp. 342-348.
148. Pedroso de Lima, M.C., Simoes, S., Pires, P., Faneca, H., and Duzgunes, N. (2001). Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv. Drug Deliv. Rev., 47, pp. 277-294.
149. Peeters, L., Sanders, N.N., Braeckmans, K., Boussery, K., de Voorde, V., d., De Smedt, S.C., and Demeester, J. (2005). Vitreous: a barrier to nonviral ocular gene therapy. Invest. Ophthalmol. Vis. Sci., 46, pp. 3553-3561.
150. Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., and Puglisi, G. (2002a). Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci., 16, pp. 53-61.
151. Pignatello, R., Bucolo, C., Spedalieri, G., Maltese, A., and Puglisi, G. (2002b). Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 23, pp. 3247-3255.
152. Prausnitz, M.R., and Noonan, J.S. (1998). Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci., 87, pp. 1479-1488.
153. Qaddoumi, M.G., Gukasyan, H.J., Davda, J., Labhasetwar, V., Kim, K.J., and Lee, V.H. (2003). Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol. Vis., 9, pp. 559-568.
154. Quinn, R.H., and Miller, S.S. (1992). Ion transport mechanisms in native human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci., 33, pp. 3513-3527.
155. Raghava, S., Hammond, M., and Kompella, U.B. (2004). Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv., 1, pp. 99-114.
156. Rana, Z.A., and Pearson, P.A. (2006). Pharmacologic treatment in diabetic macular edema. In Intraocular Drug Delivery (ed. G.J. Jaffe, P. Ashton, and P.A. Pearson), pp. 291-300. Taylor & Francis Group, LLC, New York.
157. Robinson, M.R., Lee, S.S., Kim, H., Kim, S., Lutz, R.J., Galban, C., Bungay, P.M., Yuan, P., Wang, N.S., Kim, J., and Csaky, K.G. (2006). A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res., 82, pp. 479-487.
158. Rocha, E.M., Cunha, D.A., Carneiro, E.M., Boschero, A.C., Saad, M.J., and Velloso, L.A. (2002). Identification of insulin in the tear film and insulin receptor and IGF-1 receptor on the human ocular surface. Invest. Ophthalmol. Vis. Sci., 43, pp. 963-967.
159. Rose, R.C., and Bode, A.M. (1991). Ocular ascorbate transport and metabolism. Comp. Biochem. Physiol. A: Physiol., 100, pp. 273-285.
160. Sabah, J.R., Schultz, B.D., Brown, Z.W., Nguyen, A.T., Reddan, J., and Takemoto, L.J. (2007). Transcytotic passage of albumin through lens epithelial cells. Invest. Ophthalmol. Vis. Sci., 48, pp. 1237-1244.
161. Saha, P., Kim, K.J., and Lee, V.H. (1996). A primary culture model of rabbit conjunctival epithelial cells exhibiting tight barrier properties. Curr. Eye Res., 15, pp. 1163-1169.
162. Saha, P., Yang, J.J., and Lee, V.H. (1998). Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci., 39, pp. 1221-1226.
163. Sahoo, S.K., Dilnawaz, F., and Krishnakumar, S. (2008). Nanotechnology in ocular drug delivery. Drug Discov. Today, 13, pp. 144-151.
164. Sanders, N.N., Peeters, L., Lentacker, I., Demeester, J., and De Smedt, S.C. (2007). Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J. Control Release, 122, pp. 226-235.
165. Sasaki, H., Yamamura, K., Tei, C., Nishida, K., and Nakamura, J. (1995). Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. J. Drug Target, 3, pp. 129-135.
166. Schlingemann, R.O., Hofman, P., Klooster, J., Blaauwgeers, H.G., van der, G.R., and Vrensen, G.F. (1998). Ciliary muscle capillaries have blood-tissue barrier characteristics. Exp. Eye Res., 66, pp. 747-754.
167. Schoenwald, R.D., and Huang, H.S. (1983). Corneal penetration behavior of beta-blocking agents I: physiochemical factors. J. Pharm. Sci., 72, pp. 1266-1272.
168. Schorderet, D.F., Manzi, V., Canola, K., Bonny, C., Arsenijevic, Y., Munier, F.L., and Maurer, F. (2005). D-TAT transporter as an ocular peptide delivery system. Clin. Experiment. Ophthalmol., 33, pp. 628-635.
169. Selvin, B.L. (1983). Systemic effects of topical ophthalmic medications. South. Med. J., 76, pp. 349-358.
170. Shedden, A.H., Laurence, J., Barrish, A., and Olah, T.V. (2001). Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc. Ophthalmol., 103, pp. 73-79.
171. Shen, J., Cross, S.T., Tang-Liu, D.D., and Welty, D.F. (2003). Evaluation of an immortalized retinal endothelial cell line as an in vitro model for drug transport studies across the blood-retinal barrier. Pharm. Res., 20, pp. 1357-1363.
172. Shen, J., Samul, R., Silva, R.L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S.F., Zinnen, S., Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., and Campochiaro, P.A. (2006). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther., 13, pp. 225-234.
173. Shimoyama, Y., Akihara, Y., Kirat, D., Iwano, H., Hirayama, K., Kagawa, Y., Ohmachi, T., Matsuda, K., Okamoto, M., Kadosawa, T., Yokota, H., and Taniyama, H. (2007). Expression of monocarboxylate transporter 1 in oral and ocular canine melanocytic tumors. Vet. Pathol., 44, pp. 449-457.
174. Smith, M., Omidi, Y., and Gumbleton, M. (2007). Primary porcine brain microvascular endothelial cells: biochemical and functional characterisation as a model for drug transport and targeting. J. Drug Target, 15, pp. 253-268.
175. Stewart, P.A., and Tuor, U.I. (1994). Blood-eye barriers in the rat: correlation of ultrastructure with function. J. Comp Neurol., 340, pp. 566-576.
176. Stone, T.W., and Jaffe, G.J. (2000). Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis. Am. J. Ophthalmol., 130, pp. 242-243.
177. - cotransporter in bovine corneal endothelium. Am. J. Physiol. Cell Physiol., 279, pp. C1648-C1655.
178. Sunkara, G., and Kompella, U.B. (2003). Membrane transport processes in the eye. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 13-58. Marcel Dekker, New York.
179. Tao, W., Wen, R., Laties, A., and Aguirre, G.D. (2006). Cell-based delivery systems: development of encapsulated cell technology for ophthalmic applications. In Intraocular Drug Delivery (ed. G.J. Jaffe, P. Ashton, and P.A. Pearson), pp. 111-128. Taylor & Francis Group, LLC, New York.
180. Tomalia, D.A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., and Smith, P. (1984). A new class of polymers: starburst-dendritic macromolecules. Polymer J., 17, pp. 117-132.
181. Toropainen, E., Ranta, V.P., Talvitie, A., Suhonen, P., and Urtti, A. (2001). Culture model of human corneal epithelium for prediction of ocular drug absorption. Invest. Ophthalmol. Vis. Sci., 42, pp. 2942-2948.
182. Urtti, A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev., 58, pp. 1131-1135.
183. Urtti, A., Rouhiainen, H., Kaila, T., and Saano, V. (1994). Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm. Res., 11, pp. 1278-1282.
184. Urtti, A., and Salminen, L. (1993a). Animal pharmacokinetic studies. In Ophthalmic Drug Delivery Systems (ed. A.K. Mitra), pp. 121-136. Marcel Dekker, New York.
185. Urtti, A., and Salminen, L. (1993b). Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol., 37, pp. 435-456.
186. Vandamme, T.F., and Brobeck, L. (2005). Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J. Control Release, 102, pp. 23-38.
187. Vandervoort, J., and Ludwig, A. (2007). Ocular drug delivery: nanomedicine applications. Nanomedicine, 2, pp. 11-21.
188. Vega, E., Egea, M.A., Valls, O., Espina, M., and Garcia, M.L. (2006). Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J. Pharm. Sci., 95, pp. 2393-2405.
189. Visor, G.C. (1994). Drug design strategies for ocular therapeutics. Adv. Drug Delivery Rev., 14, pp. 269-279.
190. Wood, T.O., McLaughlin, B.J., and Boykins, L.G. (1985). Electron microscopy of corneal surface microdiathermy. Curr. Eye Res., 4, pp. 885-895.
191. Wu, J., Zhang, J.J., Koppel, H., and Jacob, T.J. (1996). P-glycoprotein regulates a volume-activated chloride current in bovine non-pigmented ciliary epithelial cells. J. Physiol., 491 (Pt 3), pp. 743-755.
192. Yang, J.J., Ann, D.K., Kannan, R., and Lee, V.H. (2007). Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: its effect on drug efflux and its regulation by adenoviral infection. Pharm. Res., 24, pp. 1490-1500.
193. Zimmer, A., and Kreuter, J. (1995). Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Deliv. Rev., 16, pp. 61-73.